26th Jan 2015 07:15
LONDON (Alliance News) - Shire PLC Monday noted that NPS Pharmaceuticals Inc, which Shire is acquiring, has had its Natpara drug for hypoparathyroidism approved by the US Food and Drug administration, saying it was further evidence of the value of the deal.
The US FDA has approved Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in
patients with hypoparathyroidism, which is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone.
"The Natpara label is in line with our expectations, and we believe this approval further validates Shire's decision to acquire NPS Pharma, which is an excellent strategic fit allowing us to leverage our market expertise, core capabilities in rare disease patient management, and global footprint,2 Shire Chief Executive Flemming Ornskov said in a statement.
Shire said it hopes to be able to launch the treatment in the US once its acquisition of NPS Pharmaceuticals closes during the first quarter of 2015.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire